Edition:
United Kingdom

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

230.20CHF
16 Feb 2018
Change (% chg)

CHF2.60 (+1.14%)
Prev Close
CHF227.60
Open
CHF228.80
Day's High
CHF230.40
Day's Low
CHF228.20
Volume
13,728
Avg. Vol
34,605
52-wk High
CHF271.75
52-wk Low
CHF219.80

Select another date:

Thu, Feb 15 2018

Photo

Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio

Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion (1.35 billion pounds) to speed development of cancer medicines and support its efforts to price them based on how well they work.

Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio

Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.

UPDATE 2-Roche to buy Flatiron Health for $1.9 bln to expand cancer care portfolio

Feb 15 Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.

Roche to buy Flatiron Health for $1.9 bln

Feb 15 Drugmaker Roche Holding AG said on Thursday it would buy the rest of the privately held oncology data company Flatiron Health Inc for $1.9 billion to speed up development and delivery of breakthrough medicines for cancer patients.

BRIEF-Roche To Acquire Flatiron Health

* ROCHE SAYS UNDER TERMS OF THE AGREEMENT, ROCHE WILL MAKE A PAYMENT OF $1.9 BILLION TO FLATIRON HEALTH ON A FULLY DILUTED BASIS

BRIEF-Health Canada Approves Roche's Ocrevus For Type of Multiple Sclerosis

* HEALTH CANADA APPROVES OCREVUS® (OCRELIZUMAB) FOR CANADIANS LIVING WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)

BRIEF-Shire says too early to see impact Of Roche competitor Hemlibra

* CFO SAYS SEES IT IS STILL EARLY TO ASSESS IMPACT OF COMPETITOR ROCHE'S HEMLIBRA ON HEMOPHILIA FRANCHISE Further company coverage: (Reporting By London Bureau)

BRIEF-Roche Receives FDA Clearance For Factor Ii And Factor V Test On The Cobas® 4800 System

* ROCHE RECEIVES FDA CLEARANCE FOR FACTOR II AND FACTOR V TEST ON THE COBAS® 4800 SYSTEM Source text for Eikon: Further company coverage:

Drug copies ready to take next bite out of Roche's cancer sales

LONDON European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars.

Drug copies ready to take next bite out of Roche's cancer sales

LONDON European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focussed on so-called biosimilars.

Select another date: